Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan 3 min read Industries Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan Pharm'Up A significant financial collaboration has been finalized to dramatically accelerate the clinical development of sacituzumab tirumotecan (sac-TMT),... Read More Read more about Merck Secures $700 Million from Blackstone to Accelerate Development of Next-Generation TROP2 ADC, Sacituzumab Tirumotecan
Pharm'Up 
